Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | The promise of CD123-targeted therapy in BPDCN

Naveen Pemmaraju • 27 Aug 2022
Texas MPN Workshop 2022
Blastic Plasmacytoid Dendritic Cell Neoplasm Myeloproliferative Neoplasms Rare Diseases Antibodies CAR-T Pivekimab sunirine Tagraxofusp

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights CD123-targeting agents being explored for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), including tagraxofusp and pivekimab sunirine. Dr Pemmaraju also comments on the potential of CD123-targeted CAR-T therapy and the importance of further investigating this approach. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Naveen Pemmaraju

1:40
TAG-AZA-VEN in the treatment of patients with newly diagnosed CD123+ AML
Naveen Pemmaraju • 11 Dec 2023
1:29
Exciting developments in the field of BPDCN
Naveen Pemmaraju • 11 Dec 2023
1:58
TRANSFORM-1: navitoclax + ruxolitinib vs placebo + ruxolitinib in patients with untreated MF
Naveen Pemmaraju • 11 Dec 2023
1:15
Exploring the evolving treatment landscape of myelofibrosis
Naveen Pemmaraju • 3 Jun 2023

Related Videos

3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
0:52
Using spatial proteomics to analyze the bone marrow microenvironment in SMM treated with nivolumab
Irene Ghobrial • 7 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals